Search research articles
Contact Us
Filters
Showing results (41-50 of 114) with videos related to
Page
of 12
Sort By:
Leukemia & Lymphoma
|
October 1, 2015
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression
Xin Cao, L Jeffrey Medeiros, Yi Xia, et al.
British Journal of Haematology
|
March 22, 2021
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy
Chutima Kunacheewa, Lei Feng, Elisabet E Manasanch, et al.
Neoplasia (New York, N.Y.)
|
March 18, 2021
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia
Yingjun Wang, Vasantha Lakshmi Gali, Zijun Y Xu-Monette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density
Alyssa K Kosturakis, Zijing He, Yan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2018
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, et al.
Journal of Hematology & Oncology
|
June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis
Xin Cao, Qing Ye, Robert Z Orlowski, et al.
Leukemia & Lymphoma
|
November 10, 2020
SARS-CoV-2 in multiple myeloma: initial observation and management
Elisabet E Manasanch, Victor Mulanovich, Joanna-Grace Manzano, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 16, 2019
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
Samer Tabchi, Rajit Nair, Chutima Kunacheewa, et al.
Leukemia & Lymphoma
|
July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
Qaiser Bashir, Nina Shah, Simrit Parmar, et al.
Blood
|
August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Deborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 114) with videos related to
Sort By:
Page
of 12
Leukemia & Lymphoma
|
October 1, 2015
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression
Xin Cao, L Jeffrey Medeiros, Yi Xia, et al.
British Journal of Haematology
|
March 22, 2021
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy
Chutima Kunacheewa, Lei Feng, Elisabet E Manasanch, et al.
Neoplasia (New York, N.Y.)
|
March 18, 2021
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia
Yingjun Wang, Vasantha Lakshmi Gali, Zijun Y Xu-Monette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density
Alyssa K Kosturakis, Zijing He, Yan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2018
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, et al.
Journal of Hematology & Oncology
|
June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis
Xin Cao, Qing Ye, Robert Z Orlowski, et al.
Leukemia & Lymphoma
|
November 10, 2020
SARS-CoV-2 in multiple myeloma: initial observation and management
Elisabet E Manasanch, Victor Mulanovich, Joanna-Grace Manzano, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 16, 2019
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
Samer Tabchi, Rajit Nair, Chutima Kunacheewa, et al.
Leukemia & Lymphoma
|
July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
Qaiser Bashir, Nina Shah, Simrit Parmar, et al.
Blood
|
August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Deborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Page
of 12